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The costs included vaccination (acquisition and administration), outpatient care (influenza-like illness treatment and treatment of complications), antiviral treatment, inpatient treatment for complications, and lost productivity due to acute disease and mortality. Patterns of resource consumption were mainly based on published sources. Medical costs were from various sources, including average wholesale prices, the Centers for Disease Control and Prevention vaccine Web site, official reimbursement rates, and published claims analysis of costs associated with influenza complications. Productivity losses were based on average daily wages from the US Bureau of Labor Statistics. Costs were in US $. The price year was 2008. A 3% discount rate was applied.
Analysis of uncertainty:
Various scenario analyses were performed to test variations in model assumptions for the inclusion of an indirect effect (the base case analysis did not included reduced virus transmission or 'herd immunity'), reduced influenza-like illness risk in unvaccinated populations, lower vaccine coverage with universal mass vaccination, reduced complication in those who did not seek treatment for influenza-like illness, and reduced vaccine efficacy. All other inputs were subjected to a deterministic one-way sensitivity analysis using ranges of estimates between 75% and 125% of the base case value. A probabilistic sensitivity analysis was performed using a Monte Carlo simulation with 1,000 iterations and probability distributions for model inputs derived from the literature.
Results
In the whole US population, the targeted vaccine programme had direct/indirect costs of $114.5 billion, with 859,000 expected lifetime QALYs lost; universal mass vaccination had direct/indirect costs of $111.4, with 825,000 expected lifetime QALYs lost. Under base case assumptions, universal mass vaccination was predicted to dominate targeted vaccine programme, which was less effective and more expensive.
The likelihood of universal mass vaccination dominance was 82% in the probabilistic sensitivity analysis.
In some scenario analyses, universal mass vaccination was no longer dominant but even under unfavourable assumption, the highest incremental cost per QALY gained with universal mass vaccination over targeted vaccine programme was $15,900 (reduced complication in those who did not seek treatment for influenza-like illness), which still appeared to be a cost-effective figure.
The most influential input was the proportion of high-risk individuals aged 65 years and older who received vaccination with universal mass vaccination. This gave a 25% reduction from the base case estimate of 83.1% to 62.3% and led to an incremental cost per QALY gained of $65,900.
At a cost-effectiveness threshold of $50,000 per QALY, the net monetary benefit of universal mass vaccination was positive in 99.7% of iterations.
